Masimo Announces U.S. Release of Trace™ Data Visualization and Reporting Tool
October 05 2017 - 8:00AM
Business Wire
Masimo (NASDAQ: MASI) announced today the U.S. release of
Trace™, patient data visualization and reporting software designed
for Masimo Root® and Radical-7® monitors.
This press release features multimedia. View
the full release here:
http://www.businesswire.com/news/home/20171005005362/en/
Masimo Trace™ Data Visualization and
Reporting Tool (Photo: Business Wire)
Trace is the first data visualization and reporting software
compatible with the full capabilities of the Masimo Root Patient
Monitoring and Connectivity Platform, including Radical-7 and
Radius-7® Pulse CO-Oximeters®, Root with integrated noninvasive
blood pressure and temperature, and connected MOC-9™ modules such
as SedLine® brain function monitoring, ISA™ and ISA OR+
capnography, and O3® regional oximetry.
“Trace adds a valuable and powerful visualization resource to
clinical toolkits,” said Joe Kiani, Founder and CEO of Masimo.
“With its unique versatility and customizability and with access to
all of Masimo’s advanced measurement technologies, Trace offers
clinicians the ability to review and focus on the patient data
patterns that matter most for each case, in the format that
provides the most insight.”
Clinicians who are interested in reviewing overnight sleep
studies and who review six-minute walk patient data can benefit
from Trace’s ability to rapidly generate standard oximetry reports,
as well as customized oximetry reports that also include acoustic
respiration rate (RRa®) and end-tidal carbon dioxide (EtCO2) data.
Clinicians and researchers can download and evaluate patient data
involving advanced rainbow SET™ parameters and capnography,
SedLine, and O3 measurements. Trace can display patient data from
all of these technologies on the same time axis, facilitating
clinical case review. The ability to annotate and store data helps
clinicians build easily accessible case histories.
Trace can communicate with Masimo devices via high-speed wired
or wireless connections, with the ability to download up to 96
hours of patient data in seconds, aiding workflow efficiencies.
Trace can provide analytics such as the determination of the
minimum, maximum, and mean values for each measurement, the
percentage of time spent at defined parameter thresholds, threshold
crossing counts, and the duration of desaturation events. Visual
tools such as trend graphs, histograms, and event annotations are
also supported. Data can be tagged with notes, labelled with
identifiers, and cropped and adjusted to allow clinicians to focus
on segments and items of interest, from which a PDF report can be
generated or CSV file exported.
@MasimoInnovates | #Masimo
About Masimo
Masimo (NASDAQ: MASI) is a global leader in innovative
noninvasive monitoring technologies. Our mission is to improve
patient outcomes and reduce the cost of care. In 1995, the company
debuted Masimo SET® Measure-through Motion and Low Perfusion™ pulse
oximetry, which has been shown in multiple studies to significantly
reduce false alarms and accurately monitor for true alarms. Masimo
SET® has also been shown to help clinicians reduce severe
retinopathy of prematurity in neonates,1 improve CCHD screening in
newborns,2 and, when used for continuous monitoring with Masimo
Patient SafetyNet™* in post-surgical wards, reduce rapid response
activations and costs.3,4,5 Masimo SET® is estimated to be used on
more than 100 million patients in leading hospitals and other
healthcare settings around the world,6 and is the primary pulse
oximetry at 16 of the top 20 hospitals listed in the 2017-18 U.S.
News and World Report Best Hospitals Honor Roll.7 In 2005, Masimo
introduced rainbow® Pulse CO-Oximetry technology, allowing
noninvasive and continuous monitoring of blood constituents that
previously could only be measured invasively, including total
hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin
(SpCO®), methemoglobin (SpMet®), Pleth Variability Index (PVi®),
and more recently, Oxygen Reserve Index™ (ORi™), in addition to
SpO2, pulse rate, and perfusion index (Pi). In 2014, Masimo
introduced Root®, an intuitive patient monitoring and connectivity
platform with the Masimo Open Connect™ (MOC-9™) interface, enabling
other companies to augment Root with new features and measurement
capabilities. Masimo is also taking an active leadership role in
mHealth with products such as the Radius-7™ wearable patient
monitor, iSpO2® pulse oximeter for smartphones, and the MightySat™
fingertip pulse oximeter. Additional information about Masimo and
its products may be found at www.masimo.com. Published clinical
studies on Masimo products can be found at
http://www.masimo.com/cpub/clinical-evidence.htm.
ORi has not received FDA 510(k) clearance and is not available
for sale in the United States.
*The use of the trademark Patient SafetyNet is under license
from University HealthSystem Consortium.
References
1. Castillo A et al. Prevention of Retinopathy of Prematurity in
Preterm Infants through Changes in Clinical Practice and SpO2
Technology. Acta Paediatr. 2011 Feb;100(2):188-92.2. de-Wahl
Granelli A et al. Impact of pulse oximetry screening on the
detection of duct dependent congenital heart disease: a Swedish
prospective screening study in 39,821 newborns. BMJ. 2009;338.3.
Taenzer AH et al. Impact of Pulse Oximetry Surveillance on Rescue
Events and Intensive Care Unit Transfers: A Before-And-After
Concurrence Study. Anesthesiology. 2010; 112(2):282-287.4. Taenzer
AH et al. Postoperative Monitoring – The Dartmouth Experience.
Anesthesia Patient Safety Foundation Newsletter. Spring-Summer
2012.5. McGrath SP et al. Surveillance Monitoring Management for
General Care Units: Strategy, Design, and Implementation. The Joint
Commission Journal on Quality and Patient Safety. 2016
Jul;42(7):293-302.6. Estimate: Masimo data on file.7.
http://health.usnews.com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview.
Forward-Looking Statements
This press release includes forward-looking statements as
defined in Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934, in connection with the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, among others, statements
regarding the potential effectiveness of Masimo Trace™. These
forward-looking statements are based on current expectations about
future events affecting us and are subject to risks and
uncertainties, all of which are difficult to predict and many of
which are beyond our control and could cause our actual results to
differ materially and adversely from those expressed in our
forward-looking statements as a result of various risk factors,
including, but not limited to: risks related to our assumptions
regarding the repeatability of clinical results; risks related to
our belief that Masimo's unique noninvasive measurement
technologies, including Masimo Trace, contribute to positive
clinical outcomes and patient safety; risks related to our belief
that Masimo noninvasive medical breakthroughs provide
cost-effective solutions and unique advantages; as well as other
factors discussed in the "Risk Factors" section of our most recent
reports filed with the Securities and Exchange Commission ("SEC"),
which may be obtained for free at the SEC's website at www.sec.gov.
Although we believe that the expectations reflected in our
forward-looking statements are reasonable, we do not know whether
our expectations will prove correct. All forward-looking statements
included in this press release are expressly qualified in their
entirety by the foregoing cautionary statements. You are cautioned
not to place undue reliance on these forward-looking statements,
which speak only as of today's date. We do not undertake any
obligation to update, amend or clarify these statements or the
"Risk Factors" contained in our most recent reports filed with the
SEC, whether as a result of new information, future events or
otherwise, except as may be required under the applicable
securities laws.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171005005362/en/
MasimoEvan Lamb, 949-396-3376elamb@masimo.com
Masimo (NASDAQ:MASI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Masimo (NASDAQ:MASI)
Historical Stock Chart
From Apr 2023 to Apr 2024